VERSONO Medical Ltd is delighted to announce that it has been named Dragons’ Den winner of the CX Innovation Prize at the international CX Symposium in London last week.
The competition was between nine companies from the US, Germany, Israel, Singapore and Ireland, all of which have developed innovative technologies in the field of vascular and endovascular treatment.
VERSONO faced off in a Dragons’ Den-style event in which VERSONO Medical CEO Finbar Dolan presented on the company’s plans for its revolutionary FastWire Technology Platform, including its progress on enabling the endovascular treatment of chronic complex total occlusions (CTOs), and the latest developments in its FREEFLOW pivotal study.
VERSONO was judged the winner by a panel of Dragons including Robert Mitchell, General Manager of global healthcare company Organon; Prof. Frans Moll, vascular surgeon; Prof. Tilo Kolbel, Director of the German Aortic Centre in Hamburg; Jeffrey B. Jump, founder of Casper-Medical; and Charles Taylor, CEO of Veryan Medical. The event was chaired by Baron Stephen Greenhalgh.
The Charing Cross (CX) Symposium took place from April 23-25th at the ExcCeL in London. The event brings together world-leading experts in the treatment of vascular and endovascular disease to discuss the challenges and emerging trends in the field. Hosted every three years, the CX Symposium is a prestige event which holds education, innovation and evidence as core values.
VERSONO CEO Finbar Dolan says: “It’s an honour to win the Dragons Den innovation prize at the CX Symposium in London. This is one of the prestige events in the field of vascular and endovascular treatment and we are thrilled be selected as the standout candidates in a highly competitive group of companies developing innovative technologies.”